Publications

5674 Results

Biomarker-enriched efficacy of cetuximab-based therapy: squamous subset analysis from SWOG S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC

Authors
F Hirsch;M Redman;R Herbst;E Kim;T Semrad;L Bazhenova;G Masters;K Oettel;P Guaglianone;C Reynolds;A Karnad;S Arnold;M Varella Garcia;J Moon;P Mack;C Blanke;K Kelly;D Gandara
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 9090); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Lung
Study Number(s)
S0819

A genome-wide association study (GWAS) of survival in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503

Authors
F Innocenti;K Owzar;C Jiang;A Sibley;F Mulkey;L Carey;D Tripathy;W Barry;E Winer;C Hudis;H McLeod;M Dickler
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 538); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Breast
Study Number(s)
CTSU/C40503

Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa)

Authors
M Pomerantz;V Wang;P Kantoff;W Xie;M Kohli;G-S M Lee;E Wang;Y-H Chen;N Hahn;D Jarrard;G Liu;J Garcia;M Carducci;R DiPaola;M Freedman;C Sweeney
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 1540); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E3805

Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (Bev) for patients (pts) with stage II or III rectal cancer receiving pre-operative chemoradiation: E5204 coordinated by the Eastern Cooperative Oncology Group

Authors
AB Benson;N Meropol;P Catalano;F Zhao;E Sigurdson;A Chakravarthy;S Hamilton;P Flynn;K Kiel;C Leichman;N Petrelli;F Sinicrope;J Tepper;J Sloan;J Meyerhardt;L Wagner;P O'Dwyer
Journal / Conference
Journal Clinical Oncology 34, 2016 (suppl; abstr 3616); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/E5204

Identifying risk factors for toxicity in patients with hormone-receptor positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (Alliance) correlative study

Authors
D Li;M Dickler;L McCall;O Hahn;C Hudis;H Cohen;HB Muss;K Ballman;W Winer;D Tripathy;C Cirrincione;W Barry;A Hurria
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 10047); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Breast
Study Number(s)
CTSU/C40503

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)

Authors
G Abou-Alfa;D Niedzwieski;J Knox;A Kaubisch;J Posey;B Tan;P Kavan;K Goel;P Lammers;T Bekaii-Saab;V Tam;L Rajdev;R Kelley;A Siegel;J Balletti;J Harding;L Schwartz;R Goldberg;M Bertagnolli;A Venook
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 4003); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation
Year
2016
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80802

Impact of primary (1º) tumor location on overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405

Authors
A Venook;D Niedzwiecki;F Innocenti;M Fruth;C Greene;B O'Neil;JE Shaw;B Polite;H Hochster;C Blanke;R Goldberg;R Schilsky;R Mayer;M Bertagnolli;H Lenz
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 3504); oral American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL),
Year
2016
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

A double blind randomization to letrozole or placebo for women previously diagnosed with primary breast cancer completing five years of adjuvant aromatase inhibitor either as initial therapy or after tamoxifen (including those in the MA.17R study)

Authors
P Goss;J Ingle;H Muss;J Gralow;K Gelmon;T Whelan;K Strasser-Weippl;S Rubin;K Sturtz;A Wolff;E Winer;C Hudis;A Stopeck;JT Beck;J Salmon Kaur;K Whelan;D Tu;W Parulekar
Journal / Conference
J Clin Oncol 34 (suppl; abstr LBA1); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral
Year
2016
Research Committee(s)
Breast

The SWOG Cancer Survivor Project to Develop a Cancer Survivor Web Portal for an Individual Clinical Trial Summary

Authors
MA O'Rourke;E Lackey;K Anderson;A Gottlieb;R Krouse;C Fabian;J Klemp
Journal / Conference
Biennial Survivorship Research Conference (June 16-18, 2016, Washington, DC), poster session
Year
2016
Research Committee(s)
Cancer Survivorship

Patient reported outcomes from MA.17R: a randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 Years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer

Authors
J Lemieux;PE Goss;W Parulekar;J Ingle;K Pritchard;NJ Robert;H Muss;J Gralow;K Strasser-Weippl;MD Brundage;K Whelan;D Tu;T Whelan
Journal / Conference
Journal of Clinical Oncology 34 (suppl; abstr LBA506); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral plenary and press sessions
Year
2016
Research Committee(s)
Breast